January 24, 2024 09:59 AM EST
Financing
Startups

LB Phar­ma­ceu­ti­cals clos­es $75M Se­ries C as it be­gins PhII schiz­o­phre­nia tri­al

Kyle LaHucik

Senior Reporter

LB Phar­ma­ceu­ti­cals, a schiz­o­phre­nia biotech de­vel­op­ing a new ver­sion of a decades-old med­i­cine, has closed a $75 mil­lion Se­ries C raise and it be­gan a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times